OSCR

Oscar Health, Inc. (OSCR) - Q1 2025 Filing Summary

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended March 31, 2025. Oscar Health, Inc. operates as a single reportable segment, providing health insurance to individuals, families, and employees primarily through ACA exchanges, alongside its +Oscar technology platform. As of March 31, 2025, the company reported approximately 2.0 million effectuated members.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Total revenue increased by 42% ($904 million) year-over-year, driven primarily by a 41% increase in membership (from 1.45 million to 2.04 million effectuated members).
• Profitability: Net income attributable to Oscar Health increased by 55% to $275.3 million. Earnings from operations rose to $297.1 million.
• Expense Management: While medical expenses increased 45% due to membership growth, the SG&A expense ratio improved by 260 basis points to 15.8%, reflecting fixed cost leverage and variable cost efficiencies.
• MLR Impact: The Medical Loss Ratio increased by 120 basis points to 75.4%. Management attributed this to unfavorable prior period development related to 2024 Risk Adjustment payables, partially offset by favorable claims runout and a $24.1 million Cost Sharing Reduction (CSR) recovery accrual.
• Investment Portfolio: Net investment income increased 7% to $46.1 million due to a larger asset base. The portfolio includes significant unrealized gains on available-for-sale securities.

Guidance, Outlook, and Risks

Management Commentary & Outlook:

• Membership Trends: The company anticipates lower Special Enrollment Period (SEP) membership growth in 2025 compared to 2024, as the Medicaid redetermination "unwinding" process has largely concluded.
• Regulatory Environment: CMS has proposed "Program Integrity Rules" that may shorten open enrollment periods and tighten income verification, potentially reducing overall marketplace participation. Enhanced Advanced Premium Tax Credits (APTCs) are set to expire at the end of 2025 unless renewed by Congress.
• Tariff Risks: Potential new tariffs on pharmaceuticals and medical devices could increase medical costs and impact the ability to estimate expenses accurately.

• Convertible Notes: The company holds $305 million in 2031 Convertible Senior Notes. The conversion price condition was satisfied in Q1 2025, making the notes convertible at the holder's option during Q2 2025. No conversions have occurred as of the filing date.
• Credit Facility: A $115 million revolving credit facility remains available with no outstanding borrowings as of March 31, 2025.
• Capital Adequacy: Statutory capital and surplus for health insurance subsidiaries were estimated at $1.52 billion, exceeding minimum regulatory requirements.

• A securities class action lawsuit regarding the IPO was dismissed with prejudice in April 2025.
• The company recorded a $24.1 million estimated net recovery related to the CSR subsidy settlement.

Investor Verification Checklist

• Membership Quality: Verify the sustainability of the 41% membership growth and the impact of the anticipated slowdown in SEP enrollments on future revenue.
• MLR Volatility: Monitor the Medical Loss Ratio closely, specifically the impact of risk adjustment transfers and the potential for further unfavorable development from prior periods.
• Convertible Note Conversion: Track whether holders of the $305 million convertible notes elect to convert in Q2 2025, which could result in significant equity dilution or cash outflow.
• Regulatory Changes: Assess the final impact of CMS's proposed Program Integrity Rules and the potential expiration of enhanced APTCs at the end of 2025 on enrollment and subsidy levels.
• CSR Recovery: Confirm the timing and certainty of the $24.1 million Cost Sharing Reduction recovery cash flow.